One Capital Management LLC grew its position in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 0.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 149,903 shares of the biopharmaceutical company’s stock after buying an additional 555 shares during the period. One Capital Management LLC’s holdings in Pfizer were worth $7,681,000 as of its most recent SEC filing.
Other hedge funds also recently made changes to their positions in the company. Lam Group Inc. acquired a new position in Pfizer in the fourth quarter worth $25,000. Worth Asset Management LLC bought a new position in shares of Pfizer in the 1st quarter worth about $29,000. My Personal CFO LLC acquired a new position in shares of Pfizer in the 4th quarter valued at about $32,000. Mendota Financial Group LLC bought a new stake in shares of Pfizer during the 4th quarter valued at about $33,000. Finally, Delos Wealth Advisors LLC raised its stake in Pfizer by 100.0% during the third quarter. Delos Wealth Advisors LLC now owns 800 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 400 shares during the period. Institutional investors and hedge funds own 67.62% of the company’s stock.
Insider Activity at Pfizer
In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the firm’s stock in a transaction on Monday, May 8th. The shares were purchased at an average price of $38.58 per share, for a total transaction of $38,580.00. Following the completion of the transaction, the director now owns 6,000 shares in the company, valued at approximately $231,480. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Scott Gottlieb purchased 1,000 shares of the firm’s stock in a transaction that occurred on Monday, May 8th. The stock was acquired at an average price of $38.58 per share, for a total transaction of $38,580.00. Following the transaction, the director now directly owns 6,000 shares of the company’s stock, valued at approximately $231,480. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Pfizer Inc acquired 1,811,594 shares of the business’s stock in a transaction on Friday, March 17th. The shares were bought at an average price of $2.76 per share, for a total transaction of $4,999,999.44. Following the acquisition, the insider now owns 5,952,263 shares in the company, valued at approximately $16,428,245.88. The disclosure for this purchase can be found here. Insiders acquired a total of 1,813,594 shares of company stock valued at $5,076,999 over the last ninety days. Insiders own 0.05% of the company’s stock.
Pfizer Stock Performance
Pfizer (NYSE:PFE – Get Rating) last announced its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $1.23 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.23. The business had revenue of $18.28 billion during the quarter, compared to analyst estimates of $16.49 billion. Pfizer had a return on equity of 37.53% and a net margin of 31.25%. The company’s revenue was down 28.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.62 earnings per share. Research analysts predict that Pfizer Inc. will post 3.35 EPS for the current fiscal year.
Pfizer Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Friday, June 9th. Investors of record on Friday, May 12th were issued a $0.41 dividend. The ex-dividend date of this dividend was Thursday, May 11th. This represents a $1.64 dividend on an annualized basis and a dividend yield of 4.17%. Pfizer’s payout ratio is currently 32.28%.
Wall Street Analysts Forecast Growth
A number of equities analysts have commented on PFE shares. Morgan Stanley decreased their target price on Pfizer from $45.00 to $44.00 and set an “equal weight” rating for the company in a research note on Monday, April 10th. Cantor Fitzgerald restated an “overweight” rating on shares of Pfizer in a research note on Wednesday, May 17th. Jefferies Financial Group initiated coverage on Pfizer in a research report on Monday, March 6th. They issued a “hold” rating and a $43.00 target price on the stock. UBS Group reduced their price target on shares of Pfizer from $41.00 to $39.00 in a report on Friday, May 5th. Finally, Wells Fargo & Company dropped their price objective on shares of Pfizer from $50.00 to $44.00 and set an “equal weight” rating on the stock in a report on Friday, March 17th. Nine analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, Pfizer presently has an average rating of “Hold” and an average target price of $47.33.
About Pfizer
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Articles
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- Game-Changing News For AMD And Its Shareholders
- How to Read Stock Charts for Beginners
- Can Chegg’s AI Pivot Save It From Disruption?
- Best Investment Strategy in 2023: Determine the Right One for You
- Enovix: A Rising Power in the Lithium-Ion Industry
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
